[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 828
1. Heatley MK: Villoglandular adenocarcinoma of the uterine cervix-a systematic review of the literature. Histopathology; 2007 Aug;51(2):268-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma of the uterine cervix-a systematic review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology


2. Alcázar JL, Jurado M, López-García G: Tumor vascularization in cervical cancer by 3-dimensional power Doppler angiography: correlation with tumor characteristics. Int J Gynecol Cancer; 2010 Apr;20(3):393-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor vascularization in cervical cancer by 3-dimensional power Doppler angiography: correlation with tumor characteristics.
  • OBJECTIVE: To evaluate whether tumor vascularity as assessed by 3-dimensional power Doppler angiography (3D-PDA) correlates with some tumor features in cervical cancer.
  • METHODS: Clinical, sonographic, and histologic data on 56 women (mean age, 47.8 years; range, 27-81 years) with a diagnosis of carcinoma in the uterine cervix were analyzed.
  • CONCLUSIONS: Our data indicate that tumor vascularization as assessed by 3D-PDA correlates with some tumor features in cervical cancer.
  • [MeSH-major] Adenocarcinoma / blood supply. Carcinoma, Squamous Cell / blood supply. Imaging, Three-Dimensional. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler, Color. Uterine Cervical Neoplasms / blood supply


3. Godlewska J, Luniewski W, Zagrodzki B, Kaczmarek L, Bielawska-Pohl A, Dus D, Wietrzyk J, Opolski A, Siwko M, Jaromin A, Jakubiak A, Kozubek A, Peczyñska-Czoch W: Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline--novel cytotoxic DNA topoisomerase II inhibitors. Anticancer Res; 2005 Jul-Aug;25(4):2857-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They also showed cytotoxic activity against KB (human cervix carcinoma) cells (ID50 varied from 2.1 to 9.0 microM) and were able to overcome multidrug resistance in colorectal adenocarcinoma LoVo/DX, uterine sarcoma MES-SA/DX5 and promyelocytic leukemia HL-60/MX2 cells (the values of the resistance index RI fell between 0.54 and 2.4).

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080538.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA Adducts; 0 / Indoles; 0 / Quinolines; 0 / Topoisomerase II Inhibitors; 9007-49-2 / DNA; 91080-16-9 / calf thymus DNA
  •  go-up   go-down


Advertisement
4. Terada T: Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. Arch Gynecol Obstet; 2010 Mar;281(3):527-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman.
  • INTRODUCTION: Simultaneous occurrence of squamous cell carcinoma in situ (SIS) and adenocarcinoma in situ (AIS) is very rare in Japan.
  • A 36-year-old Japanese woman complained of abnormal uterine bleeding, and consulted to our hospital.
  • Colposcopic examination revealed irregular lesions in the cervix, and a biopsy showed simultaneous SIS and AIS.
  • The SIS corresponded to cervical intraepithelial neoplasm3, HGSIL, or carcinoma in situ, and AIS was typical AIS.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology


5. Wilting SM, Snijders PJ, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM, Albertson DG, Coffa J, Schouten JP, van de Wiel MA, Meijer CJ, Steenbergen RD: Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol; 2006 Jun;209(2):220-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix.
  • Genome-wide microarray-based comparative genomic hybridization (array CGH) was used to identify common chromosomal alterations involved in cervical carcinogenesis as a first step towards the discovery of novel biomarkers.
  • The genomic profiles of nine squamous cell carcinomas (SCCs) and seven adenocarcinomas (AdCAs), as well as four human papillomavirus (HPV)-immortalized keratinocyte cell lines, were assessed.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Chromosomes, Human, Pair 20 / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • [CommentIn] J Pathol. 2006 Oct;210(2):258-9; author reply 260 [16841301.001]
  • (PMID = 16538612.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 90421
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


6. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


7. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH: The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur J Obstet Gynecol Reprod Biol; 2009 Jul;145(1):100-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix.
  • OBJECTIVES: To evaluate the occurrence of residual or recurrent disease after loop electrosurgical excisional procedure (LEEP) for adenocarcinoma in situ (AIS) of the uterine cervix.
  • STUDY DESIGN: Records of 78 patients with a histological diagnosis of AIS of uterine cervix on LEEP who were treated and followed at our center between 1992 and 2008 were, retrospectively, reviewed.
  • Of the 47 patients with negative margins, 30 underwent subsequent hysterectomy and residual AIS, including 1 invasive adenocarcinoma, was present in 17% (5/30) of patients.
  • Of the 31 patients with positive margins, 29 patients underwent subsequent hysterectomy and residual AIS, including 4 invasive adenocarcinomas, was present in 48% (14/29) of patients.
  • CONCLUSIONS: The incidence of residual disease in patients with negative margins after LEEP for AIS of the uterine cervix is low but not negligible.
  • However, positive resection margin carries a higher risk for residual AIS or occult invasive adenocarcinoma, warranting additional LEEP or hysterectomy in these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Electrosurgery / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cervix Uteri / surgery. Female. Follow-Up Studies. Gynecologic Surgical Procedures / instrumentation. Gynecologic Surgical Procedures / methods. Humans. Hysterectomy. Incidence. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428171.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 31
  •  go-up   go-down


8. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


9. Ohta Y, Shiokawa A, Suzuki T, Kojima M: Cytology, immunohistochemistry and 3-dimensional reconstruction of adenoma malignum: a case report. Acta Cytol; 2005 Mar-Apr;49(2):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cytologic diagnosis of adenoma malignum is not easy.
  • Her chief complaint was a mucoid cervical discharge.
  • Transvaginal ultrasound examination showed multiple cervical cysts, and peculiar clusters of cervical columnar cells showing a channellike structure were observed cytologically.
  • On 3-dimensional reconstruction of normal cervical tissue, glands showing similar calibers and straight lines also had a "weeping willow-shaped" growing pattern.
  • Three-dimensional reconstruction seems to be a method that can aid in the diagnosis of adenoma malignum.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Cervix Uteri / pathology. Epithelial Cells / pathology. Uterine Cervical Neoplasms / pathology


10. Swartz RJ, West LA, Boiko I, Malpica A, Guillaud M, Macaulay C, Follen M, Atkinson EN, Cox DD: Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix. Gynecol Oncol; 2005 Dec;99(3 Suppl 1):S24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix.
  • The method was tested using data from cervical adenocarcinomas, adenocarcinoma in situ, and normal columnar tissue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Logistic Models. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


11. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology


12. Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontanière B, Snijders P, Meijer C, Franceschi S: Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer; 2005 Jan 20;113(3):483-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors.
  • A total of 198 cervical carcinoma (CC) cases (including 15 adeno- and adenosquamous carcinomas) and 202 age-matched control women were included.
  • Human papillomavirus (HPV) DNA in cervical cells was evaluated using a PCR assay.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Adenosquamous. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algeria / epidemiology. Case-Control Studies. Cervix Uteri / virology. DNA, Viral / genetics. Female. Humans. Life Style. Middle Aged. Polymerase Chain Reaction. Risk Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455386.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


13. Liu R, Pu DM, Yin L, Cheng M, Li T: [Correlation of RCAS1 expression to human papillomavirus 16 (HPV16) infection in cervical cancer]. Ai Zheng; 2007 Jun;26(6):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of RCAS1 expression to human papillomavirus 16 (HPV16) infection in cervical cancer].
  • BACKGROUND & OBJECTIVE: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is highly expressed in various human cancer cells and is related to tumor escape from host immune surveillance.
  • This study was to investigate the correlation of RCAS1 expression to human papillomavirus 16(HPV16) infection in cervical carcinoma, and explore their clinical significance.
  • METHODS: The expression of RCAS1 and HPV16 E7 protein in 71 specimens of cervical carcinoma, 76 specimens of cervical intraepithelial neoplasia, and 20 specimens of normal cervical tissue was detected by SP immunohistochemistry.
  • The positive rate of RCAS1 was 0.00% in normal cervical tissue, 39.47% in cervical intraepithelial neoplasia, and 77.46% in cervical cancerû the positive rate of HPV16 E7 was 0.05% in normal cervical tissue, 28.94% in cervical intraepithelial neoplasia, and 61.97% in cervical cancer.
  • The expression of RCAS1 in cervical cancer was significantly related to histological grade (P=0.002), but had no correlation to age, clinical stage, and histological classification (P>0.05).
  • The expression of HPV16 E7 in cervical cancer was significantly related to histological classification (P<0.001), but had no correlation to age, clinical stage, and histological grade (P>0.05).
  • RCAS1 expression was positively correlated to HPV16 infection in cervical carcinoma (r=0.780, P<0.001).
  • CONCLUSIONS: The expression of RCAS1 in cervical cancer is significantly increased, and has correlation with malignant degree of cervical carcinoma.
  • Some RCAS1-positive cervical cancer tissues are infected by HPV16.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Human papillomavirus 16. Oncogene Proteins, Viral / metabolism. Papillomavirus Infections. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / virology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cervix Uteri / virology. Female. Humans. Middle Aged. Papillomavirus E7 Proteins


14. Wang QX, Wang SZ, Liu J: [Clinical significance on atypical cervical glandular cytology]. Zhonghua Yi Xue Za Zhi; 2009 Oct 27;89(39):2779-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance on atypical cervical glandular cytology].
  • OBJECTIVE: To determine the pathological features and clinical implications of atypical glandular cells of undetermined significance (AGC) in cervical cytological results.
  • METHODS: All 87 cases of cervical cytological examinations with AGC were identified by a computerized database in our patient population.
  • The authors analyzed the cervical histopathological results by colposcopic biopsy, dilatation and curettage (D&C), cervical loop electrosurgical excision procedure (LEEP)and follow-ups. RESULTS:.
  • (1) Thirty-five cases (40.23%) had cervical and endometrial neoplasic findings: ten glandular lesions (11.49%) and squamous lesion was present in 25 patients (28.74%). (2) Among 61 patients with Pap smears subclassified as "AGC-not otherwise specified", there were 18 pathological abnormalities.
  • Ten patients with AGC as "adenocarcinoma in situ" or "adenocarcinoma" were of 6 pathological abnormalities. (3) 100% of patients with AGC had both of colposcopic and cytologic follow-ups: 1 case CIN1, 1 case CIN2 and 1 case CIN3. (4) One of 10 patients was younger than 35 years old with CGIN1 and the other 9 patient aged over 35 years old had a greater diversity of glandular lesions.
  • CONCLUSION: A finding of AGC requires both colposcopy and an aggressive workup because of a high rate of cancer and precancerous lesions.
  • Women aged over 35 years old has a greater diversity of glandular lesions and account for most cases of cervical and endometrial adenocarcinoma.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / cytology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


15. Yao TT, Dai YZ, Li SZ: [Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]. Ai Zheng; 2008 May;27(5):525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma].
  • However, its role in cervical cancer is unclear.
  • This study was to detect the expression of PI3K and Akt proteins in different cervical lesions, and to investigate the correlation of PI3K/Akt signal transduction pathway to biological behaviors of cervical carcinoma.
  • METHODS: The expression of PI3K and Akt in 76 specimens of cervical carcinoma,21 specimens of cervical intraepithelial neoplasia and 10 specimens of normal cervical epithelium were detected by SP immunohistochemistry.
  • Their correlations to clinicopathologic features of cervical carcinoma were analyzed.
  • RESULTS: The positive rates of PI3K and Akt were significantly lower in normal cervical epithelium and cervical intraepithelial neoplasia than in cervical carcinoma (0.0% and 42.9% vs. 69.7%, P<0.01;10.0% and 52.4% vs. 75.0%,P<0.01).
  • CONCLUSION: High expression of PI3K and Akt are involved in proliferation, malignant transformation, invasion and metastasis of cervical carcinoma, both of which may play important roles in the occurrence and development of human cervical carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Signal Transduction. Young Adult


16. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix.
  • OBJECTIVE: The goal of this study was to analyze the cellular distribution and possible alterations of beta-catenin and E-cadherin proteins in different histologic types of uterine cervical cancer and precursor lesions, compared to normal controls.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • We found no differences in the distribution of E-cadherin between adenocarcinomas compared with control samples.
  • CONCLUSION: Our findings indicate that cellular alterations of both beta-catenin and E-cadherin are frequent in tumors of the uterine cervix of different histologic types, and support a role for these proteins in cervical cancer development.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Trans-Activators / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin


17. de Carvalho CR, da Silva ID, Pereira JS, de Souza NC, Focchi GR, Ribalta JC: Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma. Eur J Gynaecol Oncol; 2008;29(6):590-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma.
  • OBJECTIVE: To analyze the participation of glutathione-S-transferase (GST) M1 and T1 polymorphisms associated or not with protein p53 polymorphism at codon 72 and in the presence of HPV in the carcinogenesis of uterine cervix adenocarcinoma.
  • METHODS: Forty-three samples of uterine cervix adenocarcinoma were studied and 86 samples of endocervical cells of women without tumors formed the control group.
  • RESULTS: HPV was present in 97.67% of the adenocarcinoma cases and in 31.40% of the control group.
  • CONCLUSION: The presence of GSTT1*0 increased the risk for uterine cervix adenocarcinoma development while the allele GSTT1 had a protective action.
  • The other isoforms did not appear to participate in the carcinogenesis of uterine cervix adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Alphapapillomavirus / isolation & purification. Glutathione Transferase / genetics. Polymorphism, Single Nucleotide / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115684.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


18. Csapi B, Hajdú Z, Zupkó I, Berényi A, Forgo P, Szabó P, Hohmann J: Bioactivity-guided isolation of antiproliferative compounds from Centaurea arenaria. Phytother Res; 2010 Nov;24(11):1664-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antiproliferative effects of n-hexane, chloroform and aqueous methanol extracts prepared from the whole plant of Centaurea arenaria M.B. ex Willd. were investigated against cervix adenocarcinoma (HeLa), breast adenocarcinoma (MCF7) and skin epidermoid carcinoma (A431) cells, using the MTT assay.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 21031625.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Plant Extracts; 0 / Sesquiterpenes
  •  go-up   go-down


19. Yalti S, Gürbüz B, Bilgiç R, Cakar Y, Eren S: Evaluation of cytologic screening results of the cervix. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):292-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cytologic screening results of the cervix.
  • The aim of this study was to evaluate retrospectively cytologic screening for cancers and precancerous lesions of the cervix and to research whether biopsy is overused among women with a cytologic diagnosis of atypical squamous cells of undetermined significance (ASCUS).
  • The results of the screening of 28 469 smears are as follows: 699 (2.45%) ASCUS, 67 (0.23%) low-grade squamous intraepithelial lesions (LGSIL), 43 (0.15%) high-grade squamous intraepithelial lesions (HGSIL), 1 epidermoid carcinoma, 31 (0.10%) atypical glandular cells, and 1 adenocarcinoma.
  • Histologic examination of the cervix was done in 119 patients (17.0%) of ASCUS, 13 patients (10.9%) of LGSIL, and 15 patients (12.6%) of HGSIL and cervical carcinoma.
  • In the 119 women with histological examination, histologic examination was generally performed in patients with ASCUS neoplastic Papanicolaou smear, and histologic diagnosis of low-grade, high-grade, or invasive lesion of the cervix was made in 23.5% of women with ASCUS; in these patients, 46.4% were cytologic LGSIL and 53.5 % were cytologic HGSIL and cervical carcinoma.
  • In the aspect of these findings, we concluded that for patients with a cytologic diagnosis of ASCUS, more aggressive interventions should be performed.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Papanicolaou Test. Practice Patterns, Physicians' / statistics & numerical data. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology. Vaginal Smears


20. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S: Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int; 2010 Jul;60(7):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix.
  • Immunohistochemical phenotype of these glands was compared with three normal uterine endocervices and two cases of well-differentiated mucinous adenocarcinoma of the uterine cervix.
  • On the other hand, only glands of well-differentiated mucinous adenocarcinoma expressed human gastric mucin and showed high proliferative index of Ki-67.
  • Furthermore, diffuse distribution of estrogen and progesterone receptors, lack of human gastric mucin and low proliferative activity were distinct features for endocervicosis compared to well-differentiated mucinous adenocarcinoma.
  • [MeSH-major] Cervix Uteri. Choristoma / pathology. Urinary Bladder Diseases / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Phenotype. Pregnancy. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


21. Fujii T, Nakamura M, Kameyama K, Saito M, Nishio H, Ohno A, Hirao N, Iwata T, Tsukazaki K, Aoki D: Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system. Int J Gynecol Cancer; 2010 May;20(4):605-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system.
  • INTRODUCTION: Although the colposcopic features of cervical glandular disease and cervical adenocarcinoma are not widely well known, unique microvascular patterns are reportedly useful for identifying such diseases.
  • METHODS: Twenty-one patients with adenocarcinoma in situ or early invasive adenocarcinomas were examined using digital NBI colposcopy, and the photo records were compared with those of conventional colposcopy.
  • RESULTS: Digital NBI colposcopy depicted the fine vascular texture on the surface of the cervix more clearly than conventional colposcopy.
  • The characteristic fine vascular patterns were critical for identifying cervical glandular diseases.
  • CONCLUSIONS: Digital NBI colposcopy was useful for identifying early cervical adenocarcinoma as well as adenocarcinoma in situ.
  • This system yields cervical glandular disease-related colposcopic findings that may be useful for both clinical and educational purposes.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Adenosquamous / diagnosis. Colposcopy. Diagnostic Imaging. Uterine Cervical Neoplasms / diagnosis


22. Dedecker F, Graesslin O, Bonneau S, Quéreux C: [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases]. Gynecol Obstet Fertil; 2008 Jun;36(6):616-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases].
  • [Transliterated title] Persistance et récidive des adénocarcinomes in situ après traitement: à propos d'une série rétrospective multicentrique de 121 cas.
  • OBJECTIVE: The aim of this study is to assess the results of conservative management of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Patients with cervical invasive lesions were excluded.
  • General characteristics of population, diagnosis circumstances, treatment, histology and evolution were studied.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Neoplasm Recurrence, Local / prevention & control. Papillomavirus Infections / surgery. Uterine Cervical Neoplasms / surgery


23. Roy D, Kulkarni A, Kulkarni S, Thakur MH, Maheshwari A, Tongaonkar HB: Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma. Br J Radiol; 2008 Nov;81(971):902-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma.
  • The objective of this study was to evaluate the feasibility, safety and diagnostic accuracy of transrectal ultrasound (TRUS)-guided core biopsy for recurrent carcinoma of the uterine cervix in patients with non-diagnostic vaginal cytology and transvaginal punch biopsy.17 patients with clinical and imaging suspicion of recurrent carcinoma of the cervix, and with negative cytology and punch biopsy, were referred for TRUS-guided biopsy of a recurrent mass.
  • Data were collected with respect to demography, previous diagnosis, treatment received, size and location of the recurrent lesion, and biopsy results.
  • TRUS-guided biopsy was technically successful in all of the patients and provided histological diagnosis of recurrence in 16 patients.
  • In conclusion, TRUS-guided biopsy for recurrent cervical cancer is a feasible, safe and accurate method for establishing a histopathological diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Small Cell / pathology. Cervix Uteri / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology


24. Roberts JM, Thurloe JK, Biro C, Hyne SG, Williams KE, Bowditch RC: Follow-up of cytologic predictions of endocervical glandular abnormalities: histologic outcomes in 123 cases. J Low Genit Tract Dis; 2005 Apr;9(2):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We obtained histologic follow-up for 100% of 67 cytologic predictions of adenocarcinoma in situ (AIS) and 82% of 39 predictions of possible AIS (?AIS) made over a 4-year period (1999-2002) and for 25% of 105 atypical endocervical cells (AEC) predictions over a 12-month period (2000).
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Cytodiagnosis / methods. Cytodiagnosis / standards. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Vaginal Smears


25. Kaku T, Kawano Y, Hirakawa T, Koga Y, Kobayashi H, Amada S, Ogawa S, Hagiwara T, Watanabe S, Nakano H: Cytological study of early cervical adenocarcinoma: special reference to the depth of invasion. Cytopathology; 2005 Dec;16(6):290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological study of early cervical adenocarcinoma: special reference to the depth of invasion.
  • OBJECTIVE: Early cervical adenocarcinoma (ECA) with a tumour depth of <3 mm has a good prognosis.
  • To clarify the cytological features of ECAs with depth <3 mm, these were compared with those of ECA with 3-5 mm and invasive adenocarcinoma (IA) invading the cervical wall with more than 5 mm in depth.
  • METHODS: The cervical cytological features of ECAs with depth <3 mm (14 cases) were compared with those of ECA with 3-5 mm (four cases) and IA (13 cases).
  • [MeSH-major] Adenocarcinoma / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Early Diagnosis. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis


26. Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M: CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int; 2005 Apr;55(4):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD109 expression in squamous cell carcinoma of the uterine cervix.
  • The authors have recently reported that high expression of the CD109 gene was detected in approximately half of the examined lung and esophageal squamous cell carcinomas as well as in the testis, and that CD109 has the characteristics of a cancer-testis antigen.
  • In the present study CD109 expression in cervical squamous cell carcinoma was compared with that in endometrial adenocarcinoma by reverse transcription polymerase chain reaction (RT-PCR).
  • The result demonstrated that CD109 expression is significantly higher in cervical squamous cell carcinomas than in endometrial adenocarcinomas and normal cervix and endometrium.
  • In contrast, when expression of RET finger protein (RFP) and bromodomain testis-specific (BRDT) genes, which are also known to be highly expressed in the testis, was examined, no significant difference in their expression levels was observed between squamous cell carcinomas and adenocarcinomas.
  • [MeSH-major] Antigens, CD / genetics. Carcinoma, Squamous Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Line, Tumor. DNA-Binding Proteins / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic. HeLa Cells. Humans. Neoplasm Proteins. Nuclear Proteins / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction


27. Heron DE, Axtel A, Gerszten K, Amortegui A, Kelley J, Comerci J, Edwards RP: Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: a case report in a 32-year-old female. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma of the cervix recurrent in an episiotomy scar: a case report in a 32-year-old female.
  • Cervical cancer during pregnancy is rare, occurring in approximately 3% of cervical cancer cases.
  • A sterile speculum exam in April 1997 at 31-week gestational age revealed a polyp on the anterior lip of the cervix, pathology consistent with a well-differentiated villoglandular adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Episiotomy / adverse effects. Neoplasm Recurrence, Local. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


28. Li F, Awale S, Tezuka Y, Kadota S: Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship. Biol Pharm Bull; 2009 Dec;32(12):2075-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen cycloartane-type tritepenes (1-13) and four prenylated flavanones (14-17) isolated from propolis collected in Myanmar, were evaluated for their cytotoxic activity against a panel of six different cancer cell lines; three murine cancer cell lines (colon 26-L5 carcinoma, B16-BL6 melanoma, and Lewis lung carcinoma) and three human cancer cell lines (lung A549 adenocarcinoma, cervix HeLa adenocarcinoma and HT-1080 fibrosarcoma).
  • In addition, (2S)-5,7-dihydroxy-4'-methoxy-8,3'-diprenylflavanone (14) exhibited strong cytotoxicity against all the tested cancer cell lines with the IC(50) values ranging from 14.0 to 26.4 microM.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952433.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavanones; 0 / Triterpenes; 511-64-8 / cycloartane; 9009-62-5 / Propolis
  •  go-up   go-down


29. Rubesa-Mihaljević R, Vrdoljak-Mozetic D, Ostojić DV, Stemberger-Papić S, Sindik N, Krasević M: Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report. Coll Antropol; 2010 Mar;34(1):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report.
  • Villoglandular papillary adenocarcinoma (VGA) of cervix is an uncommon but well recognized histologic subtype of cervical adenocarcinoma which usually affects young women.
  • We present a case of a 22-year-old woman admitted at our Department for glandular abnormality on cervical smear and episodes of vaginal discharge.
  • In the Pap smear, the cytological features were suspicious but not diagnostic of adenocarcinoma, therefore reported as atypical glandular cells (AGC).
  • Cervical smears examination would be helpful for an early diagnosis of VGA, however the cytologic recognition is often difficult.
  • Further investigation of the pathogenesis, diagnosis and therapy of the tumor is needed.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Severity of Illness Index. Uterine Cervical Neoplasms / pathology


30. Kawakami F, Mikami Y, Kojima A, Ito M, Nishimura R, Manabe T: Diagnostic reproducibility in gastric-type mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria. Histopathology; 2010 Mar;56(4):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic reproducibility in gastric-type mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunophenotyping. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology


31. Wood MD, Horst JA, Bibbo M: Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Cytopathol; 2007 Jan;35(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrium / pathology. Exocrine Glands / pathology. Uterine Cervical Dysplasia / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Diagnosis, Differential. Diagnostic Errors / prevention & control. Endometriosis / diagnosis. Female. Humans. Reproducibility of Results. Sensitivity and Specificity


32. Ko ML, Jeng CJ, Huang SH, Shen J, Chen SC, Tzeng CR: Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma. Taiwan J Obstet Gynecol; 2007 Mar;46(1):68-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma.
  • OBJECTIVE: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive cervical neoplasm.
  • In the present study, we present a 45-year-old woman with large cell neuroendocrine uterine cervical carcinoma with coexisting adenocarcinoma.
  • On pelvic examination, a polypoid mass of the cervix was discovered.
  • Biopsy of the lesion revealed large cell neuroendocrine carcinoma of the cervix.
  • CONCLUSION: Patients with LCNEC of the cervix have had poor prognoses; hence aggressive multimodality treatment is recommended.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Female. Humans. Middle Aged. Treatment Outcome


33. Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E: Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med; 2005 Jul;50(7):539-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Cervical cytology smears reported as AGC were reviewed and correlated with histologic follow-up.
  • Of these, 64 were classified as AGC not otherwise specified (NOS) (56.6%), 48 AGC favor neoplasia (42.5%) and 1 (0.9%) adenocarcinoma in situ.
  • Of these patients, 14 (12.4%) had endometrial involvement, whereas cervical abnormalities were identified in the remaining 16 (14.1%).
  • Older women were more likely to have involvement of the endometrium and younger women, involvement of the cervix.
  • [MeSH-major] Cervix Uteri / cytology. Cervix Uteri / pathology. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Retrospective Studies. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


34. Little L, Stewart CJ: Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol; 2010 Apr;23(4):611-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may be difficult to distinguish reactive glandular lesions from adenocarcinoma in situ of the uterine cervix, and although several immunohistochemical markers have established value in this diagnostic setting, none is completely reliable.
  • Therefore, we investigated cyclin D1 staining in a series of 64 cervical biopsy specimens including examples of normal and reactive endocervical epithelium, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesions, and invasive adenocarcinoma.
  • Thirteen specimens also included a component of high-grade cervical squamous intraepithelial neoplasia.
  • In contrast, most cases of adenocarcinoma in situ were completely negative and, therefore, cyclin D1 staining distinguished benign from neoplastic epithelial cells.
  • Although focal cyclin D1 expression was observed in 5/19 cases of adenocarcinoma in situ, the staining was associated with more marked cytological atypia precluding confusion with a reactive process.
  • The invasive adenocarcinomas were mainly negative for cyclin D1.
  • In conclusion, cyclin D1 can be included within an immunohistochemical panel to aid in the distinction between reactive cervical glandular lesions and adenocarcinoma in situ.
  • The localized distribution of staining within invasive lesions suggests that cyclin D1 up-regulation has a specific role during the progression of some endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin D1 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062011.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


35. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


36. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • On gynecological exam, there were two cervixes with a small nodule on the left cervix.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pelvic ultrasound and magnetic resonance imaging demonstrated an ectopic tumoral ureter draining a dysplastic pelvic kidney and inserted in the cervix of a bicornuate uterus.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


37. Wang Z, Zhang T, Hu H, Zhang H, Yang Z, Cui L, He W: Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett; 2008 Dec 18;272(2):242-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunotoxin OT3-DT, CDR3delta-grafted antibody OT3 chemically conjugated with diphtheria toxin (DT) showed the anti-tumor effect on the growth of several solid tumors including OEC, cervix adenocarcinoma, hepatocellular carcinoma, and rectum adenocarcinoma to various extents in nude mice.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782650.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


38. Baek KH, Lee HJ, Kim MS, Kim YS, Seong M, Lee EJ, Lee MY: Molecular cloning of rHAUSP encoding a deubiquitinating enzyme in rat testis. Oncol Rep; 2006 Jan;15(1):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The over-expression of rHAUSP induced cell death of cervical adenocarcinoma cells.


39. Hedman H, Lindström AK, Tot T, Stendahl U, Henriksson R, Hellberg D: LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol; 2010 Aug;49(6):812-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.
  • In early stage uterine cervical carcinoma, expression of LRIG1 is associated with good survival.
  • Less is known about the function and expression of LRIG2; it has not been studied in cervical carcinoma, previously.
  • MATERIALS AND METHODS: LRIG2 expression was studied by immunohistochemistry in 129 uterine cervical squamous cell carcinomas and 36 uterine cervical adenocarcinomas.
  • There was no correlation between LRIG2 expression and prognosis in the limited adenocarcinoma series.
  • DISCUSSION AND CONCLUSION: LRIG2 appears to be a significant predictor of poor prognosis in early-stage squamous cell carcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / mortality. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / mortality. Membrane Glycoproteins / metabolism. Uterine Cervical Neoplasms / mortality


40. Gudleviciene Z, Didziapetriene J, Suziedelis K, Lapkauskaite L: [Investigation of human papillomavirus, its types and variants]. Medicina (Kaunas); 2005;41(11):910-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical cancer is one of the most common cancers in Lithuania.
  • It is the fourth cancer in women according to the morbidity.
  • The incidence rate of cervical cancer has been increasing in Lithuania since 1992.
  • One of the important risk factor for cervical cancer is human papillomavirus (HPV) infection.
  • The aim of this study is to compare the prevalence of human papillomavirus among cervical cancer patients and women with cervical intraepithelial lesions and healthy women, to determine its types and HPV 16 variants.
  • Polymerase chain reaction and DNA sequencing were used for analysis of specimens taken from cervix uteri.
  • Human papillomavirus was detected in 92.7% of cervical cancer patients and in 26.7% of control women (p<0.0001).
  • HPV 16 (55.8% in squamous cell carcinoma patients and 35.3% in cervical adenocarcinoma patients) and its European HPV 16 L83V variant were detected more frequently in cervical cancer patients.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / virology. Human papillomavirus 16. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms / virology


41. Liu B, Zhang H, Zhou G, Xie Y, Hao J, Zhou Q, Duan X, Qiu R: Enhanced cell death by AdCMV-p53 after irradiation of HeLa cells with 12C 6+ ions. Eur J Obstet Gynecol Reprod Biol; 2008 Jun;138(2):226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate whether the adenovirus-mediated p53 transfer could enhance the suppression of cervix adenocarcinoma by low-dose (< or =2.0Gy) heavy-ion irradiation.
  • RESULTS: During the observation, the proportion of p53-positive cells in the C-beam with 80 MOI p53 groups was significantly higher than that in control, C-beam only, 80 MOI p53 only, and C-beam with 40 MOI p53 (p<0.05).
  • The proportion of cells in G(1)- or G(2)-phase in the C-beam with p53 groups was significantly higher than that in the C-beam only groups, or p53 only groups (p<0.05).
  • The percentage of apoptotic cells for the C-beam with p53 was significantly higher than that for the C-beam only, or p53 only (p<0.05).
  • The survival fractions for the C-beam with p53 are significantly lower than those for the C-beam only, or p53 only (p<0.05).
  • CONCLUSIONS: Adenovirus-mediated p53 transfer could enhance the suppression of cervix adenocarcinoma cells by low-dose C-beam irradiation.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / radiation effects. Genes, p53. Genetic Therapy. Heavy Ions / therapeutic use. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904269.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 7440-44-0 / Carbon
  •  go-up   go-down


42. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE: Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):792-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models.
  • BACKGROUND: Cervical carcinomas comprise two main histopathologic types, squamous cell carcinomas and adenocarcinomas.
  • METHODS: To assess potential etiologic heterogeneity of cervical cancer by histopathologic type, we examined invasive squamous cell carcinomas and adenocarcinoma cervical cancer incidence rates in the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
  • RESULTS: Squamous cell tumors (n=25,219) were nearly 5-fold more common than adenocarcinomas (n=5,451).
  • Age-adjusted incidence trends decreased for squamous cell carcinomas but increased for adenocarcinomas.
  • Cross-sectional age-specific incidence rates increased more rapidly for squamous cell carcinomas than adenocarcinomas in adolescents and young adults then leveled off for both types.
  • For squamous cell carcinoma, the APC "fitted" age-at-onset rate curve peaked before age 40 years then declined; for adenocarcinoma, the fitted curve increased rapidly until age 40 years then rose more slowly.
  • CONCLUSIONS: Despite the necessary role of HPV infection in both squamous cell carcinomas and adenocarcinomas of the cervix, secular trends and age-related natural histories differed for the two tumor types, consistent with etiologic heterogeneity.
  • Future analytic and clinical studies should consider the interaction (effect modification) of HPV infection and other cervical carcinoma risk factors by histopathologic type, time, and age.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / epidemiology. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms / classification. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258470.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


44. Tsuda H, Mikami Y, Kaku T, Hasegawa T, Akiyama F, Ohishi Y, Sasajima Y, Kasamatsu T: Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria. Pathol Int; 2005 Jul;55(7):412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria.
  • The aim of the present study was to determine if the differential diagnosis between lobular endocervical glandular hyperplasia (LEGH) and minimal deviation adenocarcinoma (MDA), or 'adenoma malignum', is reproducible when clear criteria for these two lesions are given.
  • A total of 44 proliferative endocervical glandular lesions were collected, for which differential diagnosis from MDA was considered to be necessary.
  • Seven observers independently classified these 44 lesions into LEGH, LEGH with adenocarcinoma in situ (AIS), MDA, or common cervical adenocarcinoma, according to the following criteria: LEGH was non-invasive proliferation of endocervical glandular cells without any obvious adenocarcinoma component.
  • MDA was very well-differentiated endocervical-type mucinous adenocarcinoma composed mostly of LEGH-looking glands but containing the component of obviously invasive adenocarcinoma.
  • The level increased to almost perfect (kappa = 0.928) between the group of non-invasive lesions consisting of LEGH and LEGH with AIS and the other group of invasive lesions comprising MDA and common adenocarcinoma.
  • When the modal diagnosis was adopted as the final diagnosis for individual lesions, the 5 year survival rate of patients after surgery was 100% for the non-invasive lesions but only 54% for the invasive lesions (P < 0.01).
  • It is clearly shown that reproducible differential diagnosis is possible between LEGH, LEGH with AIS, and MDA and that such a differentiation is clinically meaningful.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry / methods. Humans. Hyperplasia. Prognosis. Reproducibility of Results. Survival Analysis


45. Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N, Petrovic T, Juranic Z: Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res; 2005 Sep;24(3):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present work examines the effects of beta and alpha1-adrenoceptor antagonist carvedilol, and angiotensin converting enzyme (ACE) inhibitor captopril, on in vitro growth of tumor cell lines derived from breast tumor (MDA-MB-361), melanoma (Fem-x), cervix adenocarcinoma (HeLa) and human myelogenous leukemia (K562).
  • The order of sensitivity of various human cell lines to carvedilol's antiproliferative action was: myelogenous leukemia K562 (IC50 = 22.66 +/- 2.14 micromol), > cervix carcinoma HeLa (IC50 = 30.56 +/- 5.16 micromol), > melanoma Fem-x (IC50 = 32.17 +/- 5.75 micromol), > breast tumor MDA-MB-361 (IC50 = 35.04 +/- 2.95 micromol).
  • Understanding the action of these established and clinically accepted agents could provide a basis for design of improved therapeutic regimens in the treatment of cancer diseases.

  • Hazardous Substances Data Bank. CAPTOPRIL .
  • Hazardous Substances Data Bank. CARVEDILOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270525.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Carbazoles; 0 / Propanolamines; 0K47UL67F2 / carvedilol; 9G64RSX1XD / Captopril
  •  go-up   go-down


46. Ishioka S, Endo T, Hayashi T, Kitajima Y, Sugimura M, Sagae S, Saito T: Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer. Int J Clin Oncol; 2006 Apr;11(2):146-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer.
  • A 32-year-old Japanese woman was diagnosed as having stage Ib1 adenocarcinoma by diagnostic laser conization at a local hospital.
  • The excised uterine cervix and lymph nodes were pathologically negative for cancer.
  • This is the first successful case in Japan of delivery after vaginal RT for invasive uterine cervical cancer.
  • [MeSH-major] Pregnancy Outcome. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):1002-5 [14984977.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2273-9 [10590368.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1877-82 [10760765.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):614-23 [15350349.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1491-6 [9855586.001]
  • (PMID = 16622750.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Schilder RJ, Blessing J, Cohn DE: Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2005 Jan;96(1):103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • PURPOSE: A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix.
  • Histologic confirmation of the primary diagnosis was mandatory.
  • One patient had a grade 4 gastrointestinal adverse event (rectovaginal fistula formation attributed to the underlying cancer and not the study agent) complicated by grade 4 metabolic derangement.
  • CONCLUSIONS: Gemcitabine as a single agent had minimal activity in previously treated patients with non-squamous cell carcinoma of the uterine cervix.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589587.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 23073; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 28160; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA13633; United States / NCI NIH HHS / CA / CA15977
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


48. Wu YY, Liang MR, Li LY, Zeng SY: [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jun;43(6):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007].
  • OBJECTIVE: To analyze the changes in epidemiology and treatment of hospitalized patients with cervical cancer during 1990-2007.
  • METHODS: Overall, 4648 patients with cervical cancer were diagnosed in our hospital from Jan 1990 to Nov 2007, but only 4223 patients with initial treatment in our hospital were studied retrospectively.
  • (1) The mean age of cervical cancer patients gradually decreased over the past 18 years, from 54.4 years during 1990-1999 to 47.2 years during 2000-2007; the proportion of young patients aged < or = 35 years increased from 4.77% (89/1865) during 1990-1999 to 11.75% (277/2358) during 2000-2007. (2) The proportion of patients with cervical cancer (stage I a-II a) increased from 14.
  • 32% (267/1865) during 1990-1999 to 40.75% (961/2358) during 2000-2007, whereas the proportion of patients with cervical cancer (stage II b-IV) decreased from 85.68% (1598/1865) during 1990-1999 to 59.25% (1397/2358) during 2000-2007. (3) There was no significant change in histopathologic type of cervical cancer, and squamous cell carcinoma of cervix remained the main type of cervical cancer. (4) The treatment pattern of cervical cancer changed significantly: radiotherapy was the main method (75.28%) for cervical cancer during 1990-1999, but during 2000-2007, it was replaced by concurrent chemoradiotherapy (35.79%).
  • CONCLUSIONS: The proportion of young women with cervical cancer was increased during 1990-2007, and at the same period early stage cervical cancer increased, but late stage cervical cancer decreased.
  • It is obvious that chemotherapy has become the important therapy in cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Protocols. Cervix Uteri / pathology. Combined Modality Therapy. Female. Humans. Incidence. Inpatients. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies


49. Lee JW, Kim BG, Lee SJ, Lee SH, Park CS, Lee JH, Huh SJ, Bae DS: Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-stage carcinoma of the uterine cervix. Clin Oncol (R Coll Radiol); 2005 Sep;17(6):412-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-stage carcinoma of the uterine cervix.
  • AIMS: To evaluate the efficacy and toxicity of consolidation chemotherapy after concurrent chemoradiation (CCRT) with 5-fluorouracil (5-FU) and cisplatin in the treatment of high-risk, early stage cervical carcinoma after radical surgery.
  • MATERIALS AND METHODS: Women with clinical stage IB and IIA cervical carcinoma, initially treated with radical hysterectomy and pelvic lymphadenectomy, and who had positive pelvic lymph nodes, positive margins, parametrial involvement, or all three, were divided into either a CCRT alone group or a consolidation chemotherapy after CCRT group.
  • Rather, it may increase haematologic toxicities for women with high-risk, early stage cervical carcinoma who undergo radical surgery followed by CCRT.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Rate


50. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS: Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery.
  • Patients with recurrent uterine and cervical cancer have poor prognoses.
  • The objective of this study was to analyze the outcomes of patients with recurrent uterine and cervical cancer who had undergone attempted curative resection of pelvic bone, sidewall muscle, major blood vessels, and/or nerves.
  • We reviewed the records of all 14 patients with recurrent uterine and cervical cancer who had extended pelvic resections at our institution between June 2000 and November 2006.
  • Primary sites of disease were the uterus (11 patients) and cervix (3 patients).
  • Tumor histology was as follows: adenocarcinoma, seven; squamous cell carcinoma, three; leiomyosarcoma, three; and adenosarcoma, one.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Uterine Cervical Neoplasms / surgery


51. Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK: Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis; 2007 Jul;12(7):1229-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that upregulation of Cyclin A-dependent protein kinase 2 (Cdk2) activity is an essential event in apoptotic progression and the mitochondrial permeability transition in human cancer cells.
  • Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252195.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / bcl-2-Associated X Protein; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


52. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, Pouysségur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem; 2005 Sep 2;280(35):31132-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2006 Jun 2;281(22):15592
  • (PMID = 15994306.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  •  go-up   go-down


53. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively.
  • About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4.
  • Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


54. Han YH, Moon HJ, You BR, Park WH: The anti-apoptotic effects of caspase inhibitors on propyl gallate-treated HeLa cells in relation to reactive oxygen species and glutathione levels. Arch Toxicol; 2009 Sep;83(9):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we evaluated the anti-apoptotic effects of caspase inhibitors on PG-treated human cervix adenocarcinoma HeLa cells in relation to the changes of reactive oxygen species (ROS) and glutathione (GSH) levels.

  • Hazardous Substances Data Bank. PROPYL GALLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434396.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Annexin A5; 0 / Antioxidants; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Oligopeptides; 0 / Reactive Oxygen Species; 0 / benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0 / benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 8D4SNN7V92 / Propyl Gallate; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; GAN16C9B8O / Glutathione
  •  go-up   go-down


55. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • The rate of nodal endosalpingiosis was significantly higher in OSLMP cases (33%) compared with both cervical (0%, P<0.0001) and endometrial tumor cases (3%, P=0.0015).
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente MA, Garcia-Giménez A, Xercavins J: Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis? Gynecol Oncol; 2005 Apr;97(1):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
  • BACKGROUND: We present a case of umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer.
  • CASE: A 59-year-old woman with stage IIIB cervical adenocarcinoma underwent laparoscopic paraaortic lymphadenectomy as well as a conventional laparoscopy to assess the presence of peritoneal carcinomatosis.
  • Seven months after completion of chemoradiotherapy, the patient presented a 2.5-cm umbilical tumor involving the trocar tract together with recurrence of the cervical mass.
  • Histological examination of the excised umbilical mass showed recurrence of the cervical adenocarcinoma, with strong peritumoral CD31 immunocytochemical expression.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Neoplasm Seeding. Umbilicus / pathology. Uterine Cervical Neoplasms / pathology


57. Yang Y, Chen L, Han BS, Xu CM, Pan HZ: [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the biological function of the N-glycosylation modification of prion proteins (PrP), various eukaryotic expression vectors for the mutants with N-glycosylation modification of human PrP had been constructed and expressed.
  • With site-direct mutation technique, human PRNP gene was mutated and the obtained mutants were subcloned into eukaryotic expressing plasmid pcDNA3.1 and transiently expressed in Hela cervical adenocarcinoma cell.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755913.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Mutant Proteins; 0 / Prions
  •  go-up   go-down


58. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


59. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


60. Kim SS, Won SJ, Kim NJ, Yoo JK, Bae K, Lee KT: 3-Oxoolean-12-en-27-oic acid isolated from Aceriphyllum rossii induces caspase-8-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull; 2009 Jan;32(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3-OA-treated HL-60 cells and HeLa human cervix adenocarcinoma cells displayed several apoptotic features, such as, DNA fragmentation, DNA laddering by agarose gel electrophoresis, and hypodiploid DNA contents by flow cytometry, and 3-OA also caused the activations of caspase-8, -9 and -3.

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122287.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / FADD protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fas-Associated Death Domain Protein; 0 / Neuroprotective Agents; 0 / RNA, Messenger; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triterpenes; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 298-93-1 / thiazolyl blue; EC 3.4.21.- / HABP2 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


61. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • Microscopic examination of hysterectomy specimens indicated highly differentiated mucinous adenocarcinoma diffusely infiltrating the portion of adenomyosis of the corpus.
  • The uterine cervix showed no abnormalities.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


62. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR: Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer; 2007 Feb 1;120(3):650-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.
  • Human papillomavirus (HPV) is the central etiologic factor for cervical cancer, and prior studies suggested C. trachomatis may act as an HPV cofactor.
  • We examined the C. trachomatis-cervical cancer association by serotype, histology, HPV type in the tumor, and other HPV cofactors.
  • We conducted a population-based study in the Seattle-Puget Sound area of 302 women with invasive squamous cell carcinomas (SCC), 185 women with adenocarcinomas of the cervix (AC), and 318 HPV seropositive control women.

  • Genetic Alliance. consumer health - Cervical cancer.
  • Genetic Alliance. consumer health - Chlamydia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Chlamydia Infections.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):35-9 [10585579.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):423-30 [10712889.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1911-9 [10837170.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):221-7 [10861478.001]
  • [Cites] JAMA. 2001 Jan 3;285(1):47-51 [11150108.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):153-61 [11246844.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1934-40 [11280749.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1368-77 [11283058.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] J Infect Dis. 2002 Feb 1;185(3):324-31 [11807714.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):572 [12228133.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):681-2 [14520711.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):431-9 [15221973.001]
  • [Cites] Epidemiology. 2004 Jul;15(4):422-7 [15232402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1624-30 [15466979.001]
  • [Cites] JAMA. 1986 Apr 4;255(13):1730-4 [3081742.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1706-11 [3815368.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1272-8 [1328880.001]
  • [Cites] J Clin Microbiol. 1992 Nov;30(11):2911-6 [1452662.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):955-7 [7909014.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:101-19 [8205836.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):31-4 [9036866.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7 [9107427.001]
  • [Cites] Clin Dermatol. 1997 Mar-Apr;15(2):249-59 [9167909.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):25-31 [9212727.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Infect Dis. 1998 Jun;177(6):1710-4 [9607854.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):20-5 [10406360.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):110-5 [15756673.001]
  • [Cites] Am J Epidemiol. 2005 Oct 1;162(7):668-75 [16120706.001]
  • [Cites] Med J Aust. 2005 Nov 21;183(10):548-9 [16296981.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;64:1-378 [16755705.001]
  • (PMID = 17096345.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA094741-02; United States / NCI NIH HHS / CN / N01 CN067009; United States / NCI NIH HHS / CA / P01CA042792; United States / NCI NIH HHS / CA / CA094741-02; United States / NCI NIH HHS / CA / R03 CA094741; United States / NCI NIH HHS / CN / N01-CN-67009; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / R03CA94741
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antibodies, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS142339; NLM/ PMC4049152
  •  go-up   go-down


63. Chuang LT, Lerner DL, Liu CS, Nezhat FR: Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.
  • A combined pelvic lymphadenectomy with radical vaginal trachelectomy is an alternative to radical hysterectomy in the treatment of young women with cervical cancer desiring fertility preservation.
  • A 30-year-old woman, gravida 1, para 1, desiring fertility preservation was given the diagnosis of invasive adenocarcinoma on cervical cone excision.
  • We hope robotic-assisted radical trachelectomy will become an option for select women with early-stage cervical cancer who desire fertility preservation.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility / physiology. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery


64. Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW: Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci; 2007 Sep;98(9):1476-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article protein kinase C-delta (PKC-delta) is activated by hypoxia, increases the protein stability and transcriptional activity of HIF-1alpha in human cervical adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608772.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


65. Kałuzyński A, Olszak A, Smolarz B, Kowalczyk A, Kulig A: [Cervical glandular intraepithelial neoplasia topography and the risk of conisation]. Ginekol Pol; 2005 Oct;76(10):763-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical glandular intraepithelial neoplasia topography and the risk of conisation].
  • OBJECTIVES: The frequency of endocervical adenocarcinoma is increasing in comparison with squamous cell carcinoma and it presents a very difficult diagnostic and therapeutic problem.
  • 1) Evaluation of topography of the cervical glandular intraepithelial neoplasia (CGIN) 2) An analysis of the Human Papillomavirus (HPV) infection rate in samples.
  • MATERIALS AND METHODS: 360 amputated uterine cervix samples with histologically-proven diagnosis of cervical intraepithelial neoplasia (CIN-3) were evaluated.
  • RESULTS: Among 360 positive cervical intraepithelial glandular neoplasia samples (CIN-3) 71 (19.7%) showed coexisting glandular lesions (CGIN-1, 2, 3).
  • The lesions in endocervical glandular cells of CIGN-type were distributed from the distance up to 14 mm from the surface of cervix.
  • CIN-3 is associated in about 20% with cervical glandular intraepithelial neoplasia (CGIN).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Conization. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology


66. Petersson F, Michal M: Minute alveolar soft part sarcoma of the endocervix: the smallest ever published case. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar soft part sarcoma (ASPS) is a distinctive mesenchymal tumor of uncertain histogenesis, which is exceedingly rare in the uterine cervix.
  • Because of its seemingly much better prognosis, it is important in routine practice to distinguish ASPS from adenocarcinoma of the cervix.
  • This is facilitated by the awareness that ASPS can occur in this location and if there is doubt about the diagnosis on routinely stained sections, the appropriate immunohistochemical study should be performed.
  • Owing to the small number of published ASPSs in the cervix, the optimal treatment strategy has yet to be determined.


67. Jung YW, Kim SW, Kim S, Kim JH, Cho NH, Kim JW, Kim YT: Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
  • OBJECTIVE: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy.
  • STUDY DESIGN: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study.
  • COX-2 expression was associated with poor response to treatment and cancer-related death (P=0.043 and 0.012, respectively).
  • CONCLUSION: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma.
  • However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 1 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836124.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


68. Niwa Y, Hirose K, Nakanishi T, Nawa A, Kuzuya K, Tajima K, Hamajima N: Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol; 2005 Feb;96(2):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects.
  • OBJECTIVE: In this study, genetic polymorphisms, NQO1 C609T, GSTM1 positive/null, and GSTT1 positive/null, were examined with reference to cervical cancer risk in a population-based incident case-control study in Japanese.
  • METHODS: The cases comprised 131 cervical cancer patients: 87 cases with squamous cell carcinoma (SCC) and 44 with adenocarcinoma (ADC) or adenosquamous carcinoma (ADSC).
  • RESULTS: The cervical cancer risk was substantially elevated with smoking for all cases, SCC cases, and ADC/ADSC cases (OR = 4.50, 95% CI = 2.48-8.17, P < 0.001; OR = 5.68, 95% CI = 2.99-10.78, P < 0.001; and OR = 2.57, 95% CI = 1.09-6.08, P = 0.032; respectively).
  • Analysis of polymorphisms for GSTM1 and GSTT1 showed no significant differences between cervical cancer patients and controls.
  • CONCLUSION: This is the first report that the NQO1 gene might be important in relation to the risk of squamous cell carcinoma of the cervix.
  • [MeSH-major] NAD(P)H Dehydrogenase (Quinone) / genetics. Uterine Cervical Neoplasms / enzymology. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661231.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


69. Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB, Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol; 2008 Jan;108(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis.
  • Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model.
  • METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination.
  • RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1.
  • QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control).
  • Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3.
  • MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells).
  • Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
  • The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2003 Sep;8(3):449-58 [12946318.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4339-45 [14625284.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):833-8 [15252144.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] J Virol. 1968 May;2(5):430-9 [4301313.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2088-95 [12727824.001]
  • [Cites] Curr Biol. 2003 Jan 8;13(1):41-6 [12526743.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3191-7 [10617568.001]
  • [Cites] Gene Ther. 1997 Sep;4(9):961-8 [9349433.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72 [10419055.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):341-8 [15661219.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):519-31 [15548592.001]
  • [Cites] Gene Ther. 2006 Jan;13(1):1-7 [16121206.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36 [16361572.001]
  • [Cites] Mol Biol Rep. 2006 Mar;33(1):43-9 [16636916.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1300-10 [16622456.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):595-603 [16865275.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1319-29 [17016667.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):441-7 [17040622.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1917-26 [12204675.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):275-80 [11801569.001]
  • (PMID = 18061250.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083821-08; United States / NCI NIH HHS / CA / R01 CA083821; United States / NCI NIH HHS / CA / R01 CA083821-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS38788; NLM/ PMC2744403
  •  go-up   go-down


70. Coupienne I, Piette J, Bontems S: How to monitor NF-kappaB activation after photodynamic therapy. Methods Mol Biol; 2010;635:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, photodynamic therapy (PDT) has emerged as an attractive alternative approach for the treatment of different affections involving various forms of cancer and an increasing number of reports have highlighted the activation of the NF-kappaB following PDT treatment.
  • As a working model we will present results obtained from a 5-aminolevulinic acid-PDT treatment on cervix adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552341.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Photosensitizing Agents; 0 / Synaptotagmin I; 139874-52-5 / NF-kappaB inhibitor alpha; 88755TAZ87 / Aminolevulinic Acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


71. Matić I, Zizak Z, Simonović M, Simonović B, Godevac D, Savikin K, Juranić Z: Cytotoxic effect of wine polyphenolic extracts and resveratrol against human carcinoma cells and normal peripheral blood mononuclear cells. J Med Food; 2010 Aug;13(4):851-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the cytotoxic activity of red and white wine polyphenolic extracts and of resveratrol was evaluated against different cancer cell lines--human cervix adenocarcinoma HeLa, human breast adenocarcinoma MDA-MB-361, and human breast carcinoma MDA-MB-453--and normal human peripheral blood mononuclear cells (PBMCs).
  • Furthermore, white wine polyphenolic extract exhibited a significantly higher antiproliferative action on cancer cell lines than red wine extract.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cytotoxins / pharmacology. Flavonoids / pharmacology. Leukocytes, Mononuclear / drug effects. Phenols / pharmacology. Stilbenes / pharmacology. Uterine Cervical Neoplasms / drug therapy. Wine / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482276.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Stilbenes; Q369O8926L / resveratrol
  •  go-up   go-down


72. Hussain SK, Sundquist J, Hemminki K: Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer; 2008 Apr 15;122(8):1873-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database.
  • Familial aggregation of cervical cancer has been demonstrated previously, however aggregation of other human papillomavirus-associated anogenital, upper aerodigestive tract and skin cancers has not been fully characterized.
  • The Swedish Family-Cancer Database, which contains reliable data on cancer incidence and nuclear family linkages for all residents of Sweden between 1958 and 2004, was used to calculate standardized incidence ratios (SIR) and 95% confidence intervals for offspring site-specific cancer risks according to site-specific cancer in sibling and parental probands.
  • Offspring cancer risk was significantly increased when either a sibling or parent was affected at the same site for penile squamous cell carcinoma (SCC, SIR = 7.54), cervical adenocarcinoma (AC, SIR = 2.31), vulvar SCC (SIR = 2.27), skin SCC (SIR = 2.14), rectal AC (SIR = 1.86), in situ cervical SCC (SIR = 1.80), invasive cervical SCC (SIR = 1.77) and upper aerodigestive tract SCC (SIR = 1.57).
  • In situ cervical SCC risk in offspring was strongly influenced by siblings affected with oropharyngeal SCC (SIR = 3.17) and tonsillar SCC (SIR = 1.84).
  • Familial skin SCC was largely unassociated with anogenital or upper aerodigestive tract cancer risk in offspring.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cluster Analysis. Family. Female. Humans. Incidence. Male. Medical Record Linkage. Middle Aged. Mouth Neoplasms / epidemiology. Odds Ratio. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pharyngeal Neoplasms / epidemiology. Registries. Sweden / epidemiology. Tonsillar Neoplasms / epidemiology. Tumor Virus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074353.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Takai N, Hayashita C, Nakamura S, Narahara H, Matsumoto H: Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy. Eur J Gynaecol Oncol; 2010;31(5):573-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy.
  • Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix but a well recognized variant of cervical adenocarcinoma with a favorable prognosis generally occurring in women of child-bearing age.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


74. Herzog TJ, Monk BJ: Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol; 2007 Dec;197(6):566-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing the burden of glandular carcinomas of the uterine cervix.
  • Widespread use of the Papanicolaou test for the screening of cervical cancers has lead to a significant decline in overall incidence and mortality rates over the past 3 decades.
  • When different histologic types of cervical cancers are considered and trends are reexamined, it becomes apparent that observed declines are reflective of squamous cell carcinomas predominantly; the rates for adenocarcinomas continue to rise.
  • Reducing the incidence and mortality rates that are associated with adenocarcinomas can be accomplished by using improved screening techniques and large-scale implementation of cervical cancer vaccines that target the predominant oncogenic human papillomavirus types that are associated with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Cancer Vaccines / therapeutic use. Female. Humans. Incidence. Mass Screening. Papillomavirus Infections / complications. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use


75. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Screening has had a major impact on cervical cancer in many countries.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control


76. Cantu de Leon D, Perez Montiel D, Tabarez A, Martinez RM, Cetina L: Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors. World J Surg Oncol; 2009;7:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.
  • BACKGROUND: Synchronous gynecological tumors are rare; it is even rarer to find the rarest of gynecological tumors that of the fallopian tube, together with a histological sub-type as rare as verrucous cervix.
  • CASE PRESENTATION: We report a synchronic fallopian tube adenocarcinoma and a verrucous cervical cancer.
  • A 85-year-old woman with postmenopausal genital hemorrhage, endometrial biopsy was reported as squamous metaplasia, an exploratory laparotomy was performed finding a tubal tumor diagnosed as adenocarcinoma, a staging procedure was performed.
  • Final staging revealed IB1 cervical carcinoma and IA G3 fallopian tube carcinoma.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Cystadenocarcinoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Uterine Cervical Neoplasms / pathology


77. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of uterine malignancies.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • The concept of carcinosarcoma representing a metaplastic adenocarcinoma of the endometrium that behaves more like a carcinoma than a sarcoma is explained.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


78. Boon ME, Duineveld SM, Ouwerkerk-Noordam E, Dias D: Preneoplastic and neoplastic cervical lesions as detected in Cytoblock sections: the importance of sampling women with bleeding symptoms. Eur J Gynaecol Oncol; 2007;28(4):282-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preneoplastic and neoplastic cervical lesions as detected in Cytoblock sections: the importance of sampling women with bleeding symptoms.
  • PURPOSE OF INVESTIGATION: The purpose was to use cervical samples to prepare Cytoblocks and use the subsequent paraffin sections for additional immunostaining in our studies on angiogenesis.
  • The 261 cervical samples were processed by the Shandon Cytoblock Preparation System.
  • On the subsequent prepared Papanicolaou-stained paraffin sections a histological diagnosis was rendered on the minibiopsies.
  • In the Ki-67 stained sections, the glandular architecture of the two AIS cases and the two adenocarcinoma cases was highlighted.
  • CONCLUSION: Histologic paraffin sections provided enough minibiopsies to allow concise diagnosis including evaluation of proliferation.
  • Signs of cervical angiogenesis, including postcoital bleeding, can be a strong argument to prepare cytoblocks from samples collected by sampling brushes.
  • [MeSH-major] Cervix Uteri / pathology. Neovascularization, Pathologic / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods
  • [MeSH-minor] Adult. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Cytological Techniques / instrumentation. Cytological Techniques / methods. Female. Histological Techniques / methods. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Mass Screening. Metrorrhagia / etiology. Metrorrhagia / pathology. Middle Aged. Netherlands. Uterine Cervical Dysplasia / pathology


79. Jiang L, Malpica A, Deavers MT, Guo M, Villa LL, Nuovo G, Merino MJ, Silva EG: Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries. Int J Gynecol Pathol; 2010 Mar;29(2):146-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.
  • The majority of endometrial endometrioid adenocarcinomas involving the cervix have tumor morphology that is similar in the endometrium and the endocervix.
  • We selected 14 cases of endometrial endometrioid adenocarcinomas involving the cervix with complete pathology material available from the years between 1968 and 2004.
  • Histologic features varied between the tumors in the endometrium and the endocervix in 8 cases, and 5 of these cases had uniform, dilated glands having a microcystic appearance in the cervix.
  • The immunohistochemical studies showed some differences between the endometrial and endocervical adenocarcinomas in 8 of the 12 cases, independent of differing or similar histologic features.
  • Clonality studies showed differences between the adenocarcinoma in the endometrium and the endocervix in 7 cases, including 5 cases with different histologic appearances; 2 cases had similar loss of heterozygosity patterns.
  • However, endometrial tumors involving the cervix and endocervical tumors unrelated to HPV are both negative for high-risk HPV.
  • [MeSH-major] Carcinoma, Endometrioid / virology. Endometrial Neoplasms / virology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173500.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


80. Bai P, Ma Y, Li W, Zhang R: [Surgical intervention for the central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical intervention for the central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy].
  • OBJECTIVE: To evaluate the results of surgical treatment for central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy.
  • METHODS: Forty-seven patients were diagnosed having central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy.
  • CONCLUSION: For some patients with central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy, surgical intervention may achieve long time survival.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cervix Uteri / pathology. Cervix Uteri / surgery. Cesium Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Iridium Radioisotopes / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Young Adult


81. Connolly TP, Evans AC: Atypical Papanicolaou smear in pregnancy. Clin Med Res; 2005 Feb;3(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical glandular cells (AGC) in Papanicolaou (Pap) smears can be associated with premalignant and malignant cervical and endometrial lesions.
  • Positive diagnosis of endocervical adenocarcinoma in situ resulted in a risk-informed decision to proceed with a cold knife conization of the cervix.
  • Final pathology showed complete resection of the lesion with negative margins and an additional area of squamous dysplasia (cervical intraepithelial neoplasia, grade II to III).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Biopsy. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery


82. Hammoud AO, Deppe G, Elkhechen SS, Johnson S: Ultrasonography-guided transvaginal endometrial biopsy: a useful technique in patients with cervical stenosis. Obstet Gynecol; 2006 Feb;107(2 Pt 2):518-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonography-guided transvaginal endometrial biopsy: a useful technique in patients with cervical stenosis.
  • BACKGROUND: In patients with failed dilatation and curettage due to stenotic cervix, options for endometrial sampling are limited.
  • CASES: Two postmenopausal women presented with bleeding and failed dilatation and curettage due to a stenotic cervix.
  • Under direct transvaginal ultrasound guidance, a 20-gauge needle was inserted through the vaginal vault and anterior uterine wall into the endometrium.
  • One patient had endometrial adenocarcinoma and underwent a staging procedure.
  • CONCLUSION: The ultrasonography-guided endometrial biopsy is a viable option for endometrial sampling in the presence of stenotic cervix.
  • [MeSH-major] Endometrium / pathology. Endometrium / ultrasonography. Uterine Cervical Diseases

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449171.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Zempolich K, Fuhrman C, Milash B, Flinner R, Greven K, Ryu J, Forbes A, Kerlin K, Nichols RC, Gaffney DK: Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128. Gynecol Oncol; 2008 May;109(2):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128.
  • PURPOSE: To evaluate gene expression patterns in patients with advanced cervix cancer before and during chemoradiation in a multi-institutional cooperative group setting.
  • However, between comparison of histologic subtypes (adenocarcinoma, n=5; squamous cell carcinoma, n=17) demonstrated 45 genes differentially expressed with a false discovery rate of 0.018.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / radiotherapy. Gene Expression. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / radiotherapy


84. Xu JY, Hashi A, Kondo T, Yuminamochi T, Nara M, Hashi K, Murata S, Katoh R, Hoshi K: Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int J Gynecol Pathol; 2005 Jul;24(3):296-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia.
  • The human papillomavirus (HPV) is basically always detected in squamous cell carcinoma of the cervix and its precursors; a high incidence of HPV also has been reported in adenocarcinoma and adenocarcinoma in situ of the uterine cervix.
  • It is difficult to differentiate minimal deviation adenocarcinoma (MDA) from LEGH preoperatively or postoperatively by clinical and pathologic features.
  • As the control, HPV DNA was detected in all cases of squamous cell carcinoma and three of five cases of adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Neoplasms, Glandular and Epithelial / virology. Papillomaviridae / growth & development. Papillomavirus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968208.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


85. Sozen I, Small L, Kowalski M, Mayo SW, Hurwitz CA: Adenocarcinoma of the cervix metastatic from a colon primary and diagnosed from a routine pap smear in a 17-year-old woman: a case report. J Reprod Med; 2005 Oct;50(10):793-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the cervix metastatic from a colon primary and diagnosed from a routine pap smear in a 17-year-old woman: a case report.
  • BACKGROUND: Carcinoma metastatic to the uterine cervix is very rare.
  • The Pap smear and cervical biopsy of a 1.5-cm lesion were positive for adenocarcinoma.
  • CONCLUSION: To our knowledge, this was the youngest patient in the literature with colon cancer metastatic to the cervix.
  • This case focuses attention on the diagnostic challenge posed by an incidental finding of a cervical adenocarcinoma in the presence of an asymptomatic primary tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Papanicolaou Test. Sigmoid Neoplasms / diagnosis. Sigmoid Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / secondary. Vaginal Smears


86. Negri G, Romano F, Vittadello F, Kasal A, Mazzoleni G, Colombetti V, Egarter-Vigl E: Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri. Hum Pathol; 2006 Jun;37(6):704-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • The aim of this study was to evaluate the influence of laminin-5 (LN-5) gamma2 chain immunohistochemistry on the assessment of invasiveness in cervical adenocarcinomas and its impact on the diagnostic reproducibility of glandular lesions of the cervix uteri.
  • Immunohistochemistry with LN-5 gamma2 was performed on 30 cases, including 12 adenocarcinomas in situ (AISs), 5 AISs that were suggestive, albeit not conclusive, of infiltration (AIS+), 7 frankly invasive adenocarcinomas, and 6 nonneoplastic cases with reactive changes.
  • Diagnostic agreement between 3 observers was evaluated by kappa statistics in routine histologic specimens and with the aid of LN-5 gamma2 immunohistochemistry.
  • Laminin-5 gamma2 was expressed in 5 of the 12 AISs (41.6%), all AIS+ and invasive adenocarcinomas, and none of the reactive cases.
  • Cytoplasmatic staining was detected at the invasion front of frankly invasive adenocarcinomas and in tumor buds of all AISs with minimal stromal infiltration.
  • Overall, interobserver agreement was significantly improved by adding LN-5 gamma2 immunostains to the conventional slides (0.56 versus 0.86; P = .002).
  • After immunohistochemical evaluation, the original AIS diagnosis was unanimously changed to adenocarcinoma with minimal stromal invasion in 3 of 12 cases (25%), whereas a discordant hematoxylin-eosin diagnosis turned into a concordant one in 10 of 13 cases (6 AISs, 2 AIS+, 2 adenocarcinomas; 76.9%).
  • Immunohistochemistry with LN-5 gamma2 facilitates the assessment of the invasiveness of cervical adenocarcinomas and improves the interobserver agreement in glandular lesions of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Adhesion Molecules / analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


87. Nofech-Mozes S, Khalifa MM, Ismiil N, Dubé V, Saad RS, Sun P, Seth A, Ghorab Z: Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papilloma virus (HPV) seems to play a role in the pathogenesis of cervical squamous neoplasia and adenocarcinomas of the mucinous and endometrioid cell types.
  • Cervical serous, clear cell, and small cell carcinomas differ from the conventional endocervical adenocarcinoma in their clinical characteristics.
  • In this study, we examined the presence of high-risk HPV-DNA in rare types of cervical carcinoma using polymerase chain reaction-based test.
  • In-house cervical serous, clear cell, and small cell carcinoma cases accessioned between 2000 and 2008 were tested for HPV by polymerase chain reaction amplification of DNA extracted from deparaffinized sections using Roche AMPLICOR HPV Amplification Detection and Control Kits.
  • High-risk HPV-DNA tested positive in 3 out of 4 serous carcinomas, 2 out of 3 cervical clear cell carcinomas, and all 5 cases of small cell carcinoma and the mixed cell type.
  • Our report documents HPV status in a series of archival unusual types of adenocarcinoma of the uterine cervix.
  • Our observation is particularly significant in cervical cancer prevention as we enter the HPV vaccination era.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625948.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Fixatives; 0 / Reagent Kits, Diagnostic; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


88. Brys M, Semczuk A, Rechberger T, Krajewska WM: Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep; 2007 Jul;18(1):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the erbB-1/erbB-2 genes was measured applying the quantitative RT-PCR technique in 25 uterine carcinomas, 12 normal endometria, a carcinosarcoma and a case of botryoid sarcoma of the uterine cervix.
  • Concomitant erbB-1 and erbB-2 overexpression was detected only in 1 out of 25 (4%) uterine neoplasms. erbB-1 was overexpressed in a sarcoma botryoides of the uterine cervix.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Adenosquamous / genetics. Endometrial Neoplasms / genetics. Endometrium / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549377.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


89. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


90. Sohn MH, Kim MW, Lim ST, Lee NR, Song EK, Yim CY: Radioiodine uptake by metastatic nonthyroidal adenocarcinoma of the lung in a patient with papillary thyroid carcinoma. Clin Nucl Med; 2005 Apr;30(4):269-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioiodine uptake by metastatic nonthyroidal adenocarcinoma of the lung in a patient with papillary thyroid carcinoma.
  • A 49-year-old woman with a history of a hysterectomy for carcinoma of the cervix and papillary thyroid carcinoma showed multiple pulmonary metastases on chest radiography.
  • These lesions were found to be metastatic cervical adenocarcinoma.
  • The radioiodine uptake by the metastatic cervical adenocarcinoma of the lungs occurred in the presence of normal thyroid imaging in a patient with a thyroid nodule and papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / radionuclide imaging. Iodine Radioisotopes / pharmacokinetics. Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / radionuclide imaging. Diagnosis, Differential. Female. Humans. Middle Aged. Radiopharmaceuticals / pharmacokinetics. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / radionuclide imaging


91. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


92. Bhurgri Y, Pervez S, Kayani N, Afif M, Tahir I, Nazir K, Usman A, Faridi N, Bhurgri H, Malik J, Bashir I, Bhurgri A, Ahmed R, Hasan SH, Khurshed M, Zaidi SM: Time trends in the incidence of cancer cervix in Karachi South, 1995-2002. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):533-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in the incidence of cancer cervix in Karachi South, 1995-2002.
  • INTRODUCTION: The objective of the study was to determine the trends of cancer cervix in Karachi South during an eight (1995-2002) year period.
  • METHODOLOGY: Cancer cervix cases recorded at Karachi Cancer Registry during 1st January 1995 to 31st December 2002 were analyzed.
  • RESULTS: Cancer cervix ranked sixth in the 1995-97 period the age standardized incidence rate (ASR) world and crude incidence rate (CIR) per 100,000 were 6.81 and 3.22.
  • Thus between 1995 and 2002, the incidence of cervical cancer registered an approximate 10% increase.
  • The mean age of the cancer cases was 53.3 years (SD 11.6; 95% CI 50.58, 55.96; range 32-85 years) and 50.7 years (SD 11.7; 95% CI 48.8, 52.5; range 51 years) in period 1 and 2 respectively.
  • The morphological components of squamous cell carcinoma and adenocarcinoma remained stable during this period, though a marginally higher component and increasing incidence of adenocarcinoma was observed throughout.
  • CONCLUSION: Pakistan at present falls into a low risk cancer cervix region.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology


93. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett; 2008 Jun 8;264(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
  • This study investigated associations of Cap43 expression with angiogenesis and other clinicopathological factors in cervical adenocarcinoma.
  • The clinical records of 100 women who underwent surgery for cervical adenocarcinoma were reviewed retrospectively.
  • Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Neovascularization, Pathologic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281151.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


94. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, Kuramoto H, Unno N: Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol; 2006;27(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose.
  • PURPOSE: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.
  • Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED).
  • METHODS: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000.
  • Out of them, 13 patients had an adenocarcinoma component in pathological findings.
  • Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma.
  • CONCLUSION: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be T-BED10 > or = 100 Gy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Radiotherapy, High-Energy / methods. Salvage Therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy


95. Zhao XL, Cheng SX, Kong XD: [Expression and significance of P16INK4A and PTEN in high-risk human papillomavirus-related cervical cancer]. Ai Zheng; 2007 May;26(5):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P16INK4A and PTEN in high-risk human papillomavirus-related cervical cancer].
  • BACKGROUND & OBJECTIVE: High-risk human papillomavirus (HR-HPV) is the most important etiologic factor for cervical cancer.
  • Recent studies have revealed that abnormal expression of tumor suppressor gene P16INK4A is closely associated with HR-HPV infection during carcinogenesis of cervical epithelium.
  • Tumor suppressor gene PTEN is also involved in cervical tumorigenesis.
  • This study was to investigate the correlations of HR-HPV infection to P16INK4A and PTEN expression and its clinical significance in the carcinogenesis of cervical epithelium.
  • METHODS: The expression of P16INK4A and PTEN in 30 specimens of normal cervical tissues, 11 specimens of cancer in situ (CIS), and 24 specimens of invasive cervical carcinoma (ICC) was detected by SP immunohistochemistry; 13 types of HR-HPV DNA in these cases were detected by Hybrid Capture 2 (HC-2) assay.
  • Both HR-HPV DNA and P16INK4A overexpression (moderate or strong expression) were observed simultaneously in 21 specimens of ICC and 9 specimens of CIS; they were simultaneously negative in 20 specimens of normal cervical tissues and 1 specimen of CIS and 2 specimens of ICC.
  • Overexpression of P16INK4A was positively correlated to HR-HPV infection in cervical cancer (rs = 0.690, P<0.001).
  • PTEN was moderately or strongly expressed in 26 specimens of normal cervical tissues.
  • The positive rate of PTEN was significantly lower in ICC and CIS than in normal cervical tissues (37.5% and 36.4% vs. 83.3%, P<0.01).
  • CONCLUSIONS: P16INK4A is overexpressed in HR-HPV-infected cervical cancer, but its tumor suppressor action might be inhibited.
  • In contrast, the functional down-regulation of PTEN contributes to cervical tumorigenesis through HR-HPV-independent mechanism.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. PTEN Phosphohydrolase / metabolism. Papillomavirus Infections / genetics. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Adult. Aged. Carcinoma in Situ / metabolism. Carcinoma in Situ / virology. Cervix Uteri / metabolism. Cervix Uteri / virology. DNA, Viral / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Papillomaviridae. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672936.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


96. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One; 2008 May 28;3(5):e2303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.
  • BACKGROUND: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian cancer cell lines were investigated.
  • METHODOLOGY/PRINCIPAL FINDINGS: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial adenocarcinoma) cell lines at concentrations between 100 nM and 1 microM, while the viability of HeLa cells (epithelial cervix adenocarcinoma) or primary lung or skin fibroblasts was not affected.
  • When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model.
  • CONCLUSION/SIGNIFICANCE: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1037-45 [10400419.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):E73-9 [10559915.001]
  • [Cites] J Clin Invest. 1999 Dec;104(12):1645-53 [10606615.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4160-6 [10518606.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):58-69 [15589372.001]
  • [Cites] Biochem Pharmacol. 2005 Apr 1;69(7):1009-39 [15763539.001]
  • [Cites] J Inorg Biochem. 2005 Jul;99(7):1433-40 [15878622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9756-60 [16785432.001]
  • [Cites] Arch Pharm (Weinheim). 2007 Mar;340(3):117-26 [17315259.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 30;74(1):118-30 [17475222.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jul 1;17(13):3774-7 [17466518.001]
  • [Cites] Chem Biol Drug Des. 2007 Oct;70(4):302-10 [17937776.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2908-22 [18006686.001]
  • [Cites] J Inorg Biochem. 2008 Apr;102(4):740-7 [18180039.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):240-9 [18329084.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):441-53 [11980919.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):213-5 [12050015.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):160-2 [14522248.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8 [15361183.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 15;315(1):74-81 [7979408.001]
  • [Cites] Eur J Clin Pharmacol. 1994;47(1):1-16 [7988618.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Bioorg Med Chem. 1996 Aug;4(8):1185-96 [8879539.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1659-64 [8939847.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):789-92 [9404650.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Toxicology. 1997 Dec 31;124(3):179-92 [9482120.001]
  • [ErratumIn] PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31
  • (PMID = 18509533.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NCRR NIH HHS / RR / P20 RR018728; United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Iron(III)-salophene; 49DFR088MY / Platinum
  • [Other-IDs] NLM/ PMC2386551
  •  go-up   go-down


97. Goyal M, Kodandapani S, Sharanabasappa SN, Palanki SD: Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion. Indian J Med Paediatr Oncol; 2010 Apr;31(2):62-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion.
  • Mesothelial cell inclusions in lymph nodes are of rare occurrence and can be mistaken as metastatic adenocarcinomas, mesothelioma or sinus histiocytosis.
  • We report a case of benign mesothelial cell inclusions in cervical lymph nodes, which was associated with chylous effusion, and immunohistochemistry revealed unusual weak cytoplasmic epithelial membrane antigen positivity in the cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1264-9 [10524528.001]
  • [Cites] J Postgrad Med. 2008 Jul-Sep;54(3):230-1 [18626177.001]
  • [Cites] Histopathology. 1998 Dec;33(6):570-5 [9870153.001]
  • [Cites] Diagn Cytopathol. 1995 Jul;13(1):3-7 [7587872.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):339-46 [9563782.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):741-8 [2161177.001]
  • (PMID = 21209767.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970937
  • [Keywords] NOTNLM ; Adenocarcinoma / chylous effusion / epithelial membrane antigen / mesothelial cell inclusions
  •  go-up   go-down


98. Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J, Wang Y, Ling C: Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett; 2009 Nov 1;284(2):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells.
  • We investigated the response of human cervix adenocarcinoma HeLa cells to Corosolic acid (CRA) treatment.
  • Taken together, we believe that CRA could have strong potentials for clinical application in treating human cervix adenocarcinoma and improving cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Caspases / physiology. Mitochondria / drug effects. Neoplasm Proteins / physiology. Triterpenes / pharmacology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd.
  • (PMID = 19457606.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BAX protein, human; 0 / Drugs, Chinese Herbal; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Triterpenes; 0 / bcl-2-Associated X Protein; 4547-24-4 / corosolic acid; EC 3.4.22.- / Caspases
  •  go-up   go-down


99. Eichhorn JH, Brauns TA, Gelfand JA, Crothers BA, Wilbur DC: A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images: a feasibility study. Cancer; 2005 Aug 25;105(4):199-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images: a feasibility study.
  • BACKGROUND: Transmission over the Internet of low-resolution images acquired by automated screening of cervical cytology specimens has the potential to provide remote interpretation and, hence, centralization of a cytology workforce.
  • METHODS: Liquid-based cervical cytology slides were scanned using the FocalPoint(R) System.
  • Ten black-and-white images that had the greatest probability of containing abnormality were acquired from each of 32 reference slides (16 negative samples, 3 samples of atypical squamous cells of uncertain significance, 5 samples of low-grade squamous intraepithelial lesions [LSIL], 5 samples of high-grade squamous intraepithelial lesions [HSIL], 1 adenocarcinoma in situ sample, and 2 carcinoma samples) and were transmitted as e-mail attachments in JPEG format to remote reading stations.
  • The procedure may represent an effective way to centralize cervical cytology services and to allow the provision of services to previously unscreened populations that lack an effective cytology infrastructure.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Neoplasms, Squamous Cell / diagnosis. Telepathology / methods. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Automation. Cervix Uteri / pathology. Diagnosis, Differential. Feasibility Studies. Female. Humans. Internet. Papillomaviridae. Papillomavirus Infections / diagnosis. Reproducibility of Results. Signal Processing, Computer-Assisted


100. Seles S, Lang GE: [CAR syndrome (carcinoma-associated retinopathy syndrome) associated with an adenocarcinoma of the cervix]. Klin Monbl Augenheilkd; 2005 Sep;222(9):736-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CAR syndrome (carcinoma-associated retinopathy syndrome) associated with an adenocarcinoma of the cervix].
  • [Transliterated title] CAR-Syndrom (carcinoma-associated retinopathy syndrome) assoziiert mit einem Adenokarzinom der Zervix.
  • Due to the patient's report about a resection of an adenocarcinoma of the cervix in June 2002, she was diagnosed as having CAR syndrome.
  • One has to take into consideration that visual dysfunction can appear before the primary cancer is diagnosed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Paraneoplastic Polyneuropathy / diagnosis. Retinitis Pigmentosa / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uveitis, Intermediate / diagnosis. Vision Disorders / diagnosis






Advertisement